Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 9,039 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pulmonary Clear all
Active, not recruiting Not applicable Interventional

Pulsed-Field Ablation With/Without Electrogram Mapping

NCT07541989
View directory record Official record
Conditions
Non-paroxysmal Atrial Fibrillation
Interventions
PFA-based PVI+PWI plus adjunctive ablation guided by Electrogram Mapping of Key Substrates, PFA-based PVI+PWI alone
Procedure
Lead sponsor
Xu Liu
Other
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 30, 2026, 10:19 AM EDT
Completed No phase listed Observational

Circulating Cytokines as Predictors of Radiation Induced Pulmonary Toxicity

NCT00178230
View directory record Official record
Conditions
Lung Neoplasms
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 30, 2026, 10:19 AM EDT
Completed Not applicable Interventional

Evaluation of a Patient 'nudge' on Engagement in Lung Cancer Screening

NCT06474611
View directory record Official record
Conditions
Lung Cancer
Interventions
Patient nudge
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
50 Years to 80 Years
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 30, 2026, 10:19 AM EDT
Completed Phase 3 Interventional Results available

NVA237 Versus Placebo 12-week Efficacy Study

NCT01709864
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
NVA237, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
54
States / cities
Homewood, Alabama • Jasper, Alabama • *See Various Dept.'s*, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 30, 2026, 10:19 AM EDT
Completed Not applicable Interventional

NO Need to Ventilate: A Trial of Non-invasive Inhaled Nitric Oxide in Persistent Pulmonary Hypertension of the Newborn

NCT00139217
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
iNO, Non-invasive nitric oxide
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 30, 2026, 10:19 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer

NCT00182689
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Interventions
sorafenib tosylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 30, 2026, 10:19 AM EDT
Active, not recruiting Not applicable Interventional

Laying the Foundation for Building a Resilient KPNC Community in the Face of Worsening Air Quality Due to Wildfire Smoke

NCT07118189
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Exacerbation of COPD, Exacerbation of Chronic Obstructive Pulmonary Disease
Interventions
N95 masks and indoor air cleaner
Device
Lead sponsor
Kaiser Permanente
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 30, 2026, 10:19 AM EDT
Not listed Phase 1 Interventional

AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00324597
View directory record Official record
Conditions
Lung Cancer, Lymphoma, Lymphoproliferative Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
gemcitabine hydrochloride, motesanib diphosphate, pharmacological study
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 30, 2026, 10:19 AM EDT
Terminated Phase 1 Interventional

Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)

NCT05840510
View directory record Official record
Conditions
Solid Tumor, Adult, NSCLC, Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Interventions
Adagrasib, nab-Sirolimus
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Cleveland, Ohio • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 30, 2026, 10:19 AM EDT
Terminated Phase 1 Interventional

Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

NCT03809624
View directory record Official record
Conditions
Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma
Interventions
INBRX-105 - PDL1x41BB antibody, Pembrolizumab
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
23
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 30, 2026, 10:19 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

NCT00567359
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Erlotinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
8
States / cities
Stanford, California • Boston, Massachusetts • Peabody, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 30, 2026, 10:19 AM EDT
Terminated Phase 1 Interventional

A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy

NCT02111824
View directory record Official record
Conditions
Lung Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases
Interventions
MIMIG System, Indocyanine Green (ICG)
Device · Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 30, 2026, 10:19 AM EDT
Completed Not applicable Interventional

Electronic Support for Pulmonary Embolism Emergency Disposition

NCT03601676
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Integration of electronic clinical decision support
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
1,703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Fremont, California • Oakland, California • Redwood City, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 30, 2026, 10:19 AM EDT
Terminated Early Phase 1 Interventional

A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers

NCT01086696
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Renal Cancer, Adrenal Cancer
Interventions
FPAC
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 30, 2026, 10:19 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

NCT03052608
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Lorlatinib, Crizotinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
34
States / cities
Altamonte Springs, Florida • Brandon, Florida • Clearwater, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 30, 2026, 10:19 AM EDT
Completed Phase 4 Interventional

Bipolar Radiofrequency Ablation -Role in Prevention of Postoperative Atrial Fibrillation

NCT00765089
View directory record Official record
Conditions
Postoperative Atrial Fibrillation
Interventions
Isolation of pulmonary veins with Bipolar radiofrequency ablation
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 90 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 30, 2026, 10:19 AM EDT
Completed Not applicable Interventional

Pilot Study of a Geriatric Intervention After Colorectal and Lung Cancer Surgery

NCT01416168
View directory record Official record
Conditions
Colorectal Cancer
Interventions
McCorkle Model Intervention
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
60 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 27, 2013 · Synced Oct 30, 2026, 10:19 AM EDT
Not listed Not applicable Interventional

Whole-leg Ultrasound in Pregnant Patients

NCT01319474
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
Whole-leg compression ultrasound
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 30, 2026, 10:19 AM EDT
Completed No phase listed Observational

Hemodynamic Measurements During Liver Transplantation

NCT00682110
View directory record Official record
Conditions
Liver Transplantation
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced Oct 30, 2026, 10:19 AM EDT
Completed Not applicable Interventional Results available

Study of ECHELON ENDOPATH(TM) Staple Line Reinforcement

NCT04544865
View directory record Official record
Conditions
Gastric Procedures, Lung Resection Procedures
Interventions
Staple Line Reinforcement
Device
Lead sponsor
Ethicon Endo-Surgery
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Indianapolis, Indiana • Baton Rouge, Louisiana • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 30, 2026, 10:19 AM EDT
Terminated Not applicable Interventional

Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension

NCT02220634
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Regadenoson
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 30, 2026, 10:19 AM EDT
Active, not recruiting No phase listed Observational

DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers

NCT04165564
View directory record Official record
Conditions
Pulmonary Disease
Interventions
Institutional standard of care, Biosamples of airway and blood
Other
Lead sponsor
Boston University
Other
Eligibility
46 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 30, 2026, 10:19 AM EDT
Terminated Phase 1 Interventional

Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

NCT00179699
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
CC-5013, pemetrexed
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
5
States / cities
Orlando, Florida • Iowa City, Iowa • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2005 · Synced Oct 30, 2026, 10:19 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma

NCT06516887
View directory record Official record
Conditions
Advanced Lung Adenocarcinoma
Interventions
bemcentinib, pacritinib
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 30, 2026, 10:19 AM EDT